e aim to help our clients develop, promote and implement proposals or R&D projects highly competitive.
Genera Biotech with HORIZON 2020 SME INSTRUMENT – 2014
In Genera Biotech we interact with the best professionals and key players to be updated and to meet all the new requirements of Horizon 2020 (H2020) and assist in the development of highly competitive proposals for this funding program.
We provide support for the development of a highly impressive, original, creative, rigorous proposal that meets the special requirements and necessary details required for H2020, getting top priority in the industrial utilization of research findings. Besides the economic considerations, we concentrate in the explanation of the relevance and impact to social issues, and how the proposal can help to solve them. Genera Biotech will bring these special features in the proposal and many other of equal importance, such as the project management, to the applicant meeting the demands of today’s new H2020.
Biomarkers are used in clinical practice to describe both normal and pathological conditions. They can also have a prognostic or a predictive power. They are therefore increasingly used in medicine and many potential biomarkers are proposed every year.
Only a few of them are however validated for use in a clinical research setting. Such validation implies the demonstration of a link to a pertinent clinical endpoint or process, as well as a robust and appropriate analytical method.
The clinical validation of biomarkers will be increasingly important for the development of new diagnostics, and this is a research area where many small European companies are active.Improved clinical decisions should lead to better health outcomes while contributing to the sustainability of the health care system.
Research results should be taken up by industry, harvesting the hitherto untapped potential of nanotechnologies, advanced materials and advanced manufacturing and processing technologies. The goal is to create added value by creatively combining existing research results with other necessary elements, to transfer results across sectors where applicable, to accelerate innovation and eventually create profit or other benefits. The research should bring the technology and production to industrial readiness and maturity for commercialisation after the project.
To remain competitive, limit environmental degradation and optimise the efficient use of resources, the development of more resource-efficient and sustainable food production and processing, throughout the food system, at all scales of business, in a competitive and innovative way is required. Current food production and processing systems, especially in the SME sector, need to be revised and optimised with the aim of achieving a significant reduction in water and energy use, greenhouse gas emissions and waste generation, while at the same time improving the efficiency in the use of raw materials, increasing climate resilience and ensuring or improving shelf life, food safety and quality. New competitive eco-innovative processes should be developed, within the framework of a transition towards a more resource-efficient, sustainable circular economy.
The potential of Europe’s Oceans, seas and coasts is significant for job and growth creation if the appropriate investments in research and innovation are made. SMEs contribution to the development of the ‘Blue Growth Strategy’ (COM (2012) 494) can be significant in particular in the fields of marine biotechnology (related applications, key tools and technologies) as well as aquaculture related marine technologies and services.
However, SMEs lack access to finance to develop their activities and the economic and financial crisis has made access to finance even more difficult. This is particularly true in the previously mentioned maritime sectors, where access to finance for SMEs is considered as one of the most important barriers for the development of innovative maritime economic activities.